

# 11<sup>th</sup> Haemophilia Global Summit

## Virtual edition

24–26 September 2020

This meeting is initiated and funded by Pfizer

An independent faculty determined the structure and scientific content of the meeting

The 2020 Virtual Summit has been designed to allow participants from around the world to participate in as many live sessions as possible. Choose the time zone that best suits your location for Sessions 1 to 3 at registration.

Session 4 is pre-recorded and available 'on demand' to all participants throughout the 3-day event

## Thursday 24 September 2020

### SESSION 1: HAEMOPHILIA GENE THERAPY

TIME (CEST / EDT)		TOPIC	SPEAKER
Option 1	Option 2		
09:00 / 03:00	16:00 / 10:00	Welcome to the 11 <sup>th</sup> Haemophilia Global Summit	Steering Committee
09:10 / 03:10	16:10 / 10:10	<b>KEYNOTE ADDRESS</b> Haemophilia gene therapy: a voyage of discovery – where are we now, and where next?	Barbara Konkle (USA)
<b>HOT TOPICS IN GENE THERAPY: SLAM SESSION</b>			
09:30 / 03:30	16:30 / 10:30	AAV seropositivity and eligibility: what does it really mean?	Maria Limberis (USA)
09:40 / 03:40	16:40 / 10:40	Haemophilia gene therapy and inhibitors: the final frontier?	Jan Astermark (Sweden)
09:50 / 03:50	16:50 / 10:50	Planning for life with gene therapy: considerations for reproduction	Barbara Konkle (USA)
10:00 / 04:00	17:00 / 11:00	Gene therapy in children: if not now, when?	Steve Pipe (USA)
10:10 / 04:10	17:10 / 11:10	Gene therapy as a genetically modified material: are we ready for this in our clinic?	Gerry Dolan (UK)
10:20 / 04:20	17:20 / 11:20	Live group Q&A	<b>Moderated by:</b> Cédric Hermans (Belgium) and Jan Astermark (Sweden)
10:45 / 04:45	17:45 / 11:45	Summary and close	

AAV: Adeno-associated virus.

#### Scientific Steering Committee

The scientific content and structure of this meeting has been determined by an independent Steering Committee: Jan Astermark (Sweden), Cristina Catarino (Portugal), Gerry Dolan (UK), Cedric Hermans (Belgium)

# 11<sup>th</sup> Haemophilia Global Summit

## Virtual edition

24–26 September 2020

This meeting is initiated and funded by Pfizer

An independent faculty determined the structure and scientific content of the meeting

The 2020 Virtual Summit has been designed to allow participants from around the world to participate in as many live sessions as possible. Choose the time zone that best suits your location for Sessions 1 to 3 at registration. Session 4 is pre-recorded and available 'on demand' to all participants throughout the 3-day event

## Friday 25 September 2020

### SESSION 2: CONTEMPORARY CONSIDERATIONS IN HAEMOPHILIA CARE

TIME (CEST / EDT)		TOPIC	SPEAKER
Option 1	Option 2		
<b>INHIBITOR MANAGEMENT IN HAEMOPHILIA: SLAM SESSION</b>			
09:00 / 03:00	16:00 / 10:00	Should we still be concerned about inhibitors in 2020?	Jan Astermark (Sweden)
09:10 / 03:10	16:10 / 10:10	In 2020, should immune tolerance induction still be our first option?	Carmen Escuriola-Ettingshausen (Germany)
09:20 / 03:20	16:20 / 10:20	Practical considerations for modern-day management of inhibitors: global considerations for care	Cristina Catarino (Portugal)
09:30 / 03:30	16:30 / 10:30	Live group Q&A	Moderated by: Gerry Dolan (UK) and Cristina Catarino (Portugal)
<b>HAEMOPHILIA AND INTENSIVE SITUATIONS: SLAM SESSION</b>			
09:45 / 03:45	16:45 / 10:45	Prevention and management of thrombosis in haemophilia	Cedric Hermans (Belgium)
09:55 / 03:55	16:55 / 10:55	Getting to the heart of the matter: assessing CV risk in haemophilia	Christophe Beauloye (Belgium)
10:05 / 04:05	17:05 / 11:05	Live group Q&A	Moderated by: Gerry Dolan (UK) and Cristina Catarino (Portugal)
10:20 / 04:20	17:20 / 11:20	Summary and close	

CV: Cardiovascular.

#### Scientific Steering Committee

The scientific content and structure of this meeting has been determined by an independent Steering Committee:  
Jan Astermark (Sweden), Cristina Catarino (Portugal), Gerry Dolan (UK), Cedric Hermans (Belgium)

# 11<sup>th</sup> Haemophilia Global Summit

## Virtual edition

24–26 September 2020

This meeting is initiated and funded by Pfizer  
An independent faculty determined the structure and scientific content of the meeting

The 2020 Virtual Summit has been designed to allow participants from around the world to participate in as many live sessions as possible. Choose the time zone that best suits your location for Sessions 1 to 3 at registration. Session 4 is pre-recorded and available 'on demand' to all participants throughout the 3-day event

## Saturday 26 September 2020

### SESSION 3: HAEMOPHILIA MANAGEMENT IN 2020

TIME (CEST / EDT)		TOPIC	SPEAKER
Option 1	Option 2		
<b>HOW TO APPROACH PROPHYLAXIS IN 2020: SLAM SESSION</b>			
09:00 / 03:00	16:00 / 10:00	Prophylaxis in the younger patient: how to manage haemophilia A in 2020	Christoph Königs (Germany)
09:10 / 03:10	16:10 / 10:10	Prophylaxis in haemophilia B: what have we learned?	Dan Hart (UK)
09:20 / 03:20	16:20 / 10:20	Riding the PK curve: why activity and lifestyle are key to success in prophylaxis	Stacy Croteau (USA)
09:30 / 03:30	16:30 / 10:30	Live group Q&A	Moderated by: Jan Astermark (Sweden) and Cristina Catarino (Portugal)
<b>HAEMOPHILIA CARE IN 2020: REDEFINING "USUAL PRACTICE": SLAM SESSION</b>			
09:45 / 03:45	16:45 / 10:45	Pathogen safety: where are we now?	Gerry Dolan (UK)
09:55 / 03:55	16:55 / 10:55	Managing haemophilia in the intensive care setting	Gerry Dolan (UK)
10:05 / 04:05	17:05 / 11:05	COVID-19: lessons learned for haemophilia care in this new reality	Cedric Hermans (Belgium)
10:15 / 04:15	17:15 / 11:15	Live group Q&A	Moderated by: Jan Astermark (Sweden) and Cristina Catarino (Portugal)
10:30 / 04:30	17:30 / 11:30	Virtual Summit: Steering Committee address and event close	Steering Committee

PK: Pharmacokinetic.

**See next page for details of our on-demand programme**

#### Scientific Steering Committee

The scientific content and structure of this meeting has been determined by an independent Steering Committee:  
Jan Astermark (Sweden), Cristina Catarino (Portugal), Gerry Dolan (UK), Cedric Hermans (Belgium)

# 11<sup>th</sup> Haemophilia Global Summit

## Virtual edition

24–26 September 2020

This meeting is initiated and funded by Pfizer  
An independent faculty determined the structure and scientific content of the meeting

The 2020 Virtual Summit has been designed to allow participants from around the world to participate in as many live sessions as possible. Choose the time zone that best suits your location for Sessions 1 to 3 at registration. Session 4 is pre-recorded and available ‘on demand’ to all participants throughout the 3-day event

## Thursday 24 – Saturday 26 September 2020

### SESSION 4: ON-DEMAND CONTENT

*(10-minute presentations available on demand every day of the meeting)*

TOPIC	SPEAKER
Investigating adjuvant therapy for haemophilia	Michael Desborough (UK)
Cognitive function and haemophilia: is there a relationship?	Stacy Croteau (USA)
Brain protection: an important goal of haemophilia therapy?	Rolf Ljung (Sweden)
Haemophilia and big data: challenges and opportunities	Keith Gomez (UK)
Will “moderate” become the new “severe” in haemophilia?	Karin Fijn van Draat (Netherlands)
Telehealth and haemophilia: the eDoctor will see you now	Roshni Kulkarni (USA)

LIVE, 30-MINUTE Q&A SESSIONS FOR ON-DEMAND CONTENT (ALL TIMES CEST / EDT)	SPEAKER
Friday 25 <sup>th</sup> September at 13:00 / 07:00	<b>Moderated by:</b> Steering Committee member  <b>Faculty:</b> Presenters from on-demand sessions
Friday 25 <sup>th</sup> September at 18:00 / 12:00	
Saturday 26 <sup>th</sup> September at 13:00 / 07:00	
Saturday 26 <sup>th</sup> September at 18:00 / 12:00	

We look forward to welcoming you to the  
**11<sup>th</sup> Haemophilia Global Summit: Virtual Edition**

#### Scientific Steering Committee

The scientific content and structure of this meeting has been determined by an independent Steering Committee:  
Jan Astermark (Sweden), Cristina Catarino (Portugal), Gerry Dolan (UK), Cedric Hermans (Belgium)